We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

maandag 31 juli 2017

The Lancet: [Articles] Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of...

[Articles] Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
The benefit conferred by incorporation of bevacizumab is sustained with extended follow-up as evidenced by the overall survival curves remaining separated. After progression while receiving bevacizumab, we did not observe a negative rebound effect (ie, shorter survival after bevacizumab is stopped than after chemotherapy alone is stopped). These findings represent proof-of-concept of the efficacy and tolerability of antiangiogenesis therapy in advanced cervical cancer.
Read more

[Correspondence] Defending academic and medical independence in Turkey
We write on behalf of 207 health professionals, academics, and researchers, and 25 health and human rights organisations from many countries (appendix). We wish to bring to the attention of The Lancet's readers alarming events taking place in Turkey, where the state has been waging a campaign of terror and punishment against thousands of health professionals and academics.
Read more

[Comment] Bevacizumab in cervical cancer: a step forward for survival
Cervical cancer is the fourth most common cancer affecting women, with more than 500 000 new cases and more than 260 000 deaths worldwide in 2012.1 This statistic is disturbing given the fact that with the introduction of screening and HPV vaccination programmes, cervical cancer is now a preventable and curable disease. Once the disease is not salvageable, any treatment offered to patients is palliative. By contrast with most other solid cancers, the highest incidence of cervical cancer is in young women, with more than half of diagnoses occurring in women aged younger than 45 years.
Read more

[Seminar] Coeliac disease
Coeliac disease occurs in about 1% of people in most populations. Diagnosis rates are increasing, and this seems to be due to a true rise in incidence rather than increased awareness and detection. Coeliac disease develops in genetically susceptible individuals who, in response to unknown environmental factors, develop an immune response that is subsequently triggered by the ingestion of gluten. The disease has many clinical manifestations, ranging from severe malabsorption to minimally symptomatic or non-symptomatic presentations.
Read more

[Seminar] Thalassaemia
Inherited haemoglobin disorders, including thalassaemia and sickle-cell disease, are the most common monogenic diseases worldwide. Several clinical forms of α-thalassaemia and β-thalassaemia, including the co-inheritance of β-thalassaemia with haemoglobin E resulting in haemoglobin E/β-thalassaemia, have been described. The disease hallmarks include imbalance in the α/β-globin chain ratio, ineffective erythropoiesis, chronic haemolytic anaemia, compensatory haemopoietic expansion, hypercoagulability, and increased intestinal iron absorption.
Read more